Form 4: Mirum CFO Executes Planned Stock Sale and Option Exercise

Mirum Pharmaceuticals CFO Eric Bjerkholt sold 5,000 shares and exercised 2,393 stock options under a pre-arranged 10b5-1 trading plan.

Summary

• CFO Eric Bjerkholt sold a total of 5,000 shares of Mirum Pharmaceuticals common stock on June 8, 2026.
• The sales were executed at weighted average prices of $92.84, $93.95, and $95.12 per share.
• On June 9, 2026, the CFO exercised 2,393 stock options at an exercise price of $26.49 per share.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 9, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine financial management by an executive.

Positives

• The transactions were executed under a pre-established 10b5-1 plan, indicating the sales were not based on sudden non-public information.
• The CFO continues to maintain a significant equity stake of 47,181 shares following these transactions.

Negatives

• The filing reflects a net reduction in the CFO's direct beneficial ownership of common stock.

Risks

• Future stock price volatility could impact the value of the remaining equity held by the reporting person.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and diversify portfolios without triggering market concerns regarding material non-public information.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives at biotech firms like Mirum to ensure compliance with SEC regulations.
• The volume of shares sold is consistent with typical executive compensation and liquidity management patterns for mid-cap pharmaceutical companies.

Stakeholder Impact

• Minimal impact expected on shareholders as the transactions were pre-planned and disclosed in accordance with SEC requirements.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

MIRM, Mirum Pharmaceuticals, Insider Trading, Form 4, CFO, Stock Options, 10b5-1